- Home
- Products
- Customized FluoroAb™
- GUCY2C
- Anti-GUCY2C MAb (Clone 2)-iFluor® 555 Succinimidyl Ester
Anti-GUCY2C MAb (Clone 2)-iFluor® 555 Succinimidyl Ester (CAT#: WJY0-LS15810)
- TARGET
- ANTIBODY
- DYE
- Name
- GUCY2C
- Alternative Names
- GUCY2C; DIAR6; GUC2C; MECIL; MUCIL; STAR; guanylate cyclase 2C; GC-C
- Overview
- Human Anti-GUCY2C Antibody (Clone 2)
- Species Reactivity
- Human
- Name
- iFluor® 555 Succinimidyl Ester
- Color
- Yellow
- Excitation⁄Emission (nm)
- 557/570
- Detection method
- Fluorescent
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for WJY0-LS15810. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-403 | Anti-GUCY2C-MMAE ADC | Cleavable peptide linker | MMAE (Monomethyl auristatin E) |
| ADC-W-210 | Anti-GUCY2C-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-209 | Anti-GUCY2C-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CD248 MAb (Clone 3)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS2657)
- Anti-CD19 MAb (Clone 13)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS835)
- Anti-CD3E MAb (Clone 19)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS10364)
- Anti-ERBB3 MAb (Clone 10)-iFluor® 460 Succinimidyl Ester (CAT#: WJY0-LS8948)
- Anti-CD37 MAb (Clone 6)-iFluor® 450 Succinimidyl Ester (CAT#: WJY0-LS7194)
- Anti-CD19 MAb (Clone 32)-iFluor® 555 Succinimidyl Ester (CAT#: WJY0-LS16318)
- Anti-IFNA1 MAb (Clone 7)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS12045)
- Anti-DLL3 MAb (Clone 8)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS14754)
- Ruplizumab-Fluoresein (CAT#: ADC-FL-790)
- Anti-CA9 MAb (Clone 4)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS2122)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
